NCT04055532Withdrawn
Biomarkers in Neurodegenerative Diseases
Source: ClinicalTrials.gov · Last updated 12 Nov 2019
Reason given: Lack of regulatory approval
Brief summary (registry, in English)
The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.
- Status (registry)
- Withdrawn
- Study type
- Observational
- Enrollment
- 0 (actual)
- First submitted
- 12 Aug 2019
- Start date
- 1 Oct 2019
- Primary completion date
- 1 Oct 2024
- Lead sponsor
- University of Minnesota
- Diseases
- Alzheimer disease, Frontotemporal dementia, Lewy body dementia, Epilepsy, HIV, ALS (motor neurone disease)
- NCT number
- NCT04055532
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any conditions that could account for cognitive deficits in addition to a neurodegenerative disease, including but not limited to:
- Past or present diagnosis of Korsakoff's syndrome
- Alcohol or substance abuse preceding dementia \& still present within 5 years of onset
- Present untreated vitamin B12 or folate deficiency
- Present untreated hypothyroidism
- Past or present head trauma with persistent deficits
- Present untreated syphilis
- Past or present multiple sclerosis or another neuro-inflammatory disorder
- Past or present vascular or multi-infarct dementia
- Past or present diagnosis of huntington's disease
- Past or present normal pressure hydrocephalus
- Past or present central nervous system (CNS) lesions deemed to be clinically significant
- Unresolved or present subdural hematoma
- Past or present Ischemic Vascular Dementia
- Past or present intracerebral hemorrhage
- Present systematic liver disease
- Present renal insufficiency requiring dialysis
- Present encephalitis or meningitis
- Present anxiety disorder (not due to dementia and requiring medication more than 3x per week)
- Present severe periventricular white matter disease or greater than grade 4 white matter lesions
- Present lacunar infarcts deemed to clinically significant
- Present cortical stroke
- Present respiratory condition requiring oxygen
- Present significant systemic medical illness, such as cancer requiring chemotherapy or end stage cardiac insufficiency
- Present current medication likely to affect CNS functions:
- Benzodiazepines (no triazolam, but other short-acting benzodiazepines are OK)
- Antidepressant therapy with amitriptyline or doxepin or tx not stable during past year
- Neuroleptics in the phenothiazine and haloperidol families (atypicals OK)
- Narcotics (codeine is OK, but hold 24 hours before neuropsychological testing)
- Anti-seizure medication outside of therapeutic ranges
- Antihistamines (> 3x per week; hold 24 hours before neuropsychological testing)
Other
- Present inability to safely scan in an MRI
- Present pregnancy or lactation - Female participants will be asked to confirm that they are not pregnant and do not plan to become pregnant.
Who the study is looking for
- Diagnosis of MCI, AD, DLB, FTLD, PDD, TEA, TLE, SCA, HAND, ALS, PLS, or normal control.
- Age 18 or older
- Reliable informant with frequent contact with participant
- Mini Mental State Exam (MMSE) ≥15 AND/OR Clinical Dementia Rating (CDR) less than 2
- Able to undergo extensive psychometric testing
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Minnesota | Minneapolis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.